Children represent a minority of total COVID-19 cases, but studies have reported severe
disease and death in pediatric patients. Remdesivir (RDV) has recently demonstrated …

OBJECTIVES: Remdesivir shortens time to recovery in adults with severe coronavirus
disease 2019 (COVID-19), but its efficacy and safety in children are unknown. We describe …

Background: Millions of children in the United States have been infected with severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), with many infections leading to …

Following the emergence of the SARS-CoV-2 pandemic, finding efficient forms of treatment
is seen as a priority for both adults and children. On April 25, 2022, remdesivir has become …

Background Although coronavirus disease 2019 (COVID-19) is a mild infection in most
children, a small proportion develop severe or critical illness. Data describing agents with …

Introduction Remdesivir is a nucleoside analog that inhibits viral RNA replication by blocking
RNA-dependent RNA polymerase. First developed and tested during the Ebola epidemic …

We describe 2 expremature infants presenting with SARS-CoV-2-related pulmonary disease
in their second and fifth week of life needing support with mechanical ventilation. Both …

Remdesivir (Veklury®), a nucleotide analogue prodrug with broad-spectrum antiviral activity,
is approved for the treatment of coronavirus disease 2019 (COVID-19), the illness caused by …

FDA Approval of Remdesivir On October 22, 2020, on the basis of the results of three phase
3 clinical trials, the FDA approved remdesivir for use in adults and pediatric patients (12 …

Remdesivir is an RNA polymerase inhibitor that is commonly used in the treatment of
patients with severe acute coronavirus disease 2019 (COVID-19). As the severe acute …